Alice in Wonderland Syndrome: Diagnostic Workup and Management
For patients presenting with Alice in Wonderland syndrome (AIWS), immediately pursue auxiliary investigations including blood tests, EEG, and brain MRI to identify the underlying etiology, then direct treatment at the suspected cause—though reassurance alone suffices in approximately 50% of cases 1.
Understanding AIWS
AIWS is characterized by distortions of visual perception (micropsia, macropsia, teleopsia, metamorphopsia), alterations in body schema, and disrupted time perception 1, 2. The syndrome predominantly affects children and adolescents, with an average age of 8.1 years at presentation 2.
Diagnostic Workup Algorithm
Initial Clinical Assessment
Look specifically for:
- Visual distortions: Micropsia (69% of cases), teleopsia (50%), macropsia (25%), metamorphopsia (15%), pelopsia (10%) 2
- Time perception abnormalities (tachysensia)
- Auditory distortions
- Body image alterations
- Depersonalization/derealization
Critically, patients maintain full orientation and insight during episodes—this distinguishes AIWS from psychotic disorders 3.
Mandatory Investigations
All patients require:
Comprehensive blood work 1:
- Complete metabolic panel
- Inflammatory markers (ESR, CRP)
- Infectious serologies: Particularly EBV (VCA IgM/IgG, EBNA-1 IgG) 3
- Autoimmune screening if indicated
Etiology-Based Evaluation
Age-specific patterns matter:
Children/adolescents (≤18 years): Encephalitis is the primary concern 1
Adults/elderly: Neurological disorders predominate 1
- Consider stroke workup if vascular risk factors present 5
- Evaluate for structural lesions
Common etiologies by frequency:
What NOT to Order
- Routine karyotyping, chromosomal microarray, or genetic panels are not indicated—these are for neurodevelopmental disorders, not AIWS
- Extensive metabolic screening unless specific clinical indicators present
- Lumbar puncture only if encephalitis or CNS infection strongly suspected based on fever, altered consciousness, or focal neurological signs
Management Strategy
Primary Approach
For 50% of patients, reassurance is sufficient 1. Explain that:
- Symptoms are not harmful
- Episodes are typically self-limited
- Full recovery is expected in most cases
Etiology-Directed Treatment
When migraine is identified or develops:
- Initiate migraine prophylaxis 6
- Low-tyramine diet 6
- Standard migraine medications
- Note: 25% of patients without initial migraine history may develop migraines later 2
For infection-related AIWS:
- Supportive care during acute illness 3
- Symptoms typically resolve within 4 weeks post-infection 3
- No specific antiviral treatment needed for EBV-associated cases
For stroke-related AIWS:
- Standard stroke management
- Consider quetiapine for associated hallucinations/psychosis 5
Antipsychotic Use: Critical Caveat
Antipsychotics have limited utility 6. AIWS has a neurological, not psychiatric, origin. Use antipsychotics only for:
- Severe distress unresponsive to reassurance
- Associated psychotic features in stroke patients 5
Follow-Up and Prognosis
Expected outcomes at follow-up:
- 40% have complete resolution with no recurrence 2
- 20% experience a few additional episodes that eventually cease 2
- 40% continue having intermittent symptoms 2
- 27% develop migraines subsequently 2
- 7% develop seizures 2
Follow-up schedule:
- Close outpatient monitoring for first 4-6 weeks 3
- Re-evaluate if symptoms persist beyond expected timeframe
- Screen for migraine development in subsequent visits 2
Critical Pitfalls to Avoid
- Do not misdiagnose as schizophrenia or psychotic disorder 7—patients with AIWS maintain insight and orientation
- Do not skip neuroimaging—while usually normal, it's essential to exclude serious pathology 2
- Do not over-investigate with genetic testing—AIWS is not a genetic neurodevelopmental disorder
- Do not rush to pharmacotherapy—half of patients need only reassurance 1
- Do not dismiss symptoms in elderly patients—consider stroke, especially with right hemisphere involvement 4, 5